The UK Competition Authority accepts legally binding commitments from a pharma company to continue supplying a key bipolar drug at an affordable price (Essential Pharma)

KEYWORDS
References

UK Competition Authority, Essential Pharma, Commitments decision n-50951, 18 December 2020

UK Competition Authority, Essential Pharma, Press release, 18 December 2020

The UK Competition and Markets Authority (CMA) published today its decision accepting binding commitments from Essential Pharma (EP) to continue supplying for at least 5 years a medicine for the first line treatment of bipolar

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
    Belgium 141 contributions 48951 visits
  • Van Bael & Bellis (Brussels)
    Belgium 45 contributions 22846 visits
  • Van Bael & Bellis (Brussels)
    Belgium 44 contributions 21944 visits

Quotation

Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The UK Competition Authority accepts legally binding commitments from a pharma company to continue supplying a key bipolar drug at an affordable price (Essential Pharma), 18 December 2020, e-Competitions Commitment Decisions, Art. N° 98496

Visites 430

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues